AC
KYMR icon

Armistice Capital’s Kymera Therapeutics KYMR Stock Holding History

Armistice Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.99M Buy
83,876
+2,711
+3% +$215K 0.12% 107
2025
Q4 		$6.32M Buy
+81,165
New +$5.48M 0.08% 121

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Armistice Capital's KYMR Position: Q1 2026 in Review

Armistice Capital increased its Kymera Therapeutics (KYMR) stake by 3.3% in Q1 2026, buying an estimated $215K and bringing the position to 83,876 shares worth $6.99M. The position accounts for 0.12% of the portfolio, ranked #107.

Armistice Capital first reported a position in KYMR in Q4 2025 and has held it in 2 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Armistice Capital held 83,876 shares of Kymera Therapeutics worth $6.99M as of Q1 2026.
  • Armistice Capital bought 2,711 Kymera Therapeutics shares in Q1 2026, an estimated $215K.
  • Kymera Therapeutics made up 0.12% of Armistice Capital's portfolio in Q1 2026, its #107 holding.
  • Armistice Capital first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.